{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:50:36Z","timestamp":1789901436964,"version":"4.0.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Struct Mol Biol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41594-026-01792-w","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:00:56Z","timestamp":1776697256000},"page":"567-576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cracking the code of native amyloid fibrils: advances and next steps to enable pathology-informed therapeutic and diagnostic"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7682-8320","authenticated-orcid":false,"given":"Hilal A.","family":"Lashuel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"1792_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41586-023-06437-2","volume":"621","author":"SHW Scheres","year":"2023","unstructured":"Scheres, S. H. W., Ryskeldi-Falcon, B. & Goedert, M. Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids. Nature 621, 701\u2013710 (2023).","journal-title":"Nature"},{"key":"1792_CR2","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1016\/j.neuron.2024.05.012","volume":"112","author":"TW Todd","year":"2024","unstructured":"Todd, T. W., Islam, N. N., Cook, C. N., Caulfield, T. R. & Petrucelli, L. Cryo-EM structures of pathogenic fibrils and their impact on neurodegenerative disease research. Neuron 112, 2269\u20132288 (2024).","journal-title":"Neuron"},{"key":"1792_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-023-01694-8","volume":"11","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. Cryo-EM structures of A\u03b240 filaments from the leptomeninges of individuals with Alzheimer\u2019s disease and cerebral amyloid angiopathy. Acta Neuropathol. Commun. 11, 191 (2023).","journal-title":"Acta Neuropathol. Commun."},{"key":"1792_CR4","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.43584","volume":"8","author":"W Zhang","year":"2019","unstructured":"Zhang, W. et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer\u2019s and Pick\u2019s diseases. eLife 8, e43584 (2019).","journal-title":"eLife"},{"key":"1792_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44489-0","volume":"15","author":"K Sharma","year":"2024","unstructured":"Sharma, K. et al. Cryo-EM observation of the amyloid key structure of polymorphic TDP-43 amyloid fibrils. Nat. Commun. 15, 486 (2024).","journal-title":"Nat. Commun."},{"key":"1792_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104876","volume":"141","author":"HA Lashuel","year":"2020","unstructured":"Lashuel, H. A. Do Lewy bodies contain alpha-synuclein fibrils? And does it matter? A brief history and critical analysis of recent reports. Neurobiol. Dis. 141, 104876 (2020).","journal-title":"Neurobiol. Dis."},{"key":"1792_CR7","doi-asserted-by":"publisher","unstructured":"Lewis, A. J. et al. Ultrastructural diversity and subcellular organization of nigral Lewy pathology in Parkinson\u2019s disease. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.07.25.605088 (2024).","DOI":"10.1101\/2024.07.25.605088"},{"key":"1792_CR8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","volume":"22","author":"SH Shahmoradian","year":"2019","unstructured":"Shahmoradian, S. H. et al. Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 22, 1099\u20131109 (2019).","journal-title":"Nat. Neurosci."},{"key":"1792_CR9","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1038\/s41593-023-01484-4","volume":"26","author":"M Zielinski","year":"2023","unstructured":"Zielinski, M. et al. Cryo-EM of A\u03b2 fibrils from mouse models find tg-APPArcSwe fibrils resemble those found in patients with sporadic Alzheimer\u2019s disease. Nat. Neurosci. 26, 2073\u20132080 (2023).","journal-title":"Nat. Neurosci."},{"key":"1792_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","volume":"133","author":"E Drummond","year":"2017","unstructured":"Drummond, E. & Wisniewski, T. Alzheimer\u2019s disease: experimental models and reality. Acta Neuropathol. 133, 155\u2013175 (2017).","journal-title":"Acta Neuropathol."},{"key":"1792_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14020151","volume":"14","author":"A Sturchio","year":"2024","unstructured":"Sturchio, A. et al. Recalibrating the why and whom of animal models in Parkinson disease: a clinician\u2019s perspective. Brain Sci. 14, 151 (2024).","journal-title":"Brain Sci."},{"key":"1792_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cbpa.2021.05.006","volume":"64","author":"HA Lashuel","year":"2021","unstructured":"Lashuel, H. A. Rethinking protein aggregation and drug discovery in neurodegenerative diseases: shy we need to embrace complexity? Curr. Opin. Chem. Biol. 64, 67\u201375 (2021).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"1792_CR13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.76494","volume":"11","author":"S L\u00f6vestam","year":"2022","unstructured":"L\u00f6vestam, S. et al. Assembly of recombinant tau into filaments identical to those of Alzheimer\u2019s disease and chronic traumatic encephalopathy. eLife 11, e76494 (2022).","journal-title":"eLife"},{"key":"1792_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107326","volume":"300","author":"P Duan","year":"2024","unstructured":"Duan, P., El Mammeri, N. & Hong, M. Milligram-scale assembly and NMR fingerprint of tau fibrils adopting the Alzheimer\u2019s disease fold. J. Biol. Chem. 300, 107326 (2024).","journal-title":"J. Biol. Chem."},{"key":"1792_CR15","first-page":"RP104778","volume":"14","author":"S L\u00f6vestam","year":"2025","unstructured":"L\u00f6vestam, S. et al. Twelve phosphomimetic mutations induce the assembly of recombinant full-lengthhuman tau into paired helical filaments. eLife 14, RP104778 (2025).","journal-title":"eLife"},{"key":"1792_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30585-0","volume":"13","author":"AJ Dregni","year":"2022","unstructured":"Dregni, A. J. et al. Fluent molecular mixing of tau isoforms in Alzheimer\u2019s disease neurofibrillary tangles. Nat. Commun. 13, 2967 (2022).","journal-title":"Nat. Commun."},{"key":"1792_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107730","volume":"300","author":"P Duan","year":"2024","unstructured":"Duan, P. et al. Alzheimer\u2019s disease seeded tau forms paired helical filaments yet lacks seeding potential. J. Biol. Chem. 300, 107730 (2024).","journal-title":"J. Biol. Chem."},{"key":"1792_CR18","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/2211-5463.13657","volume":"13","author":"A Tarutani","year":"2023","unstructured":"Tarutani, A. et al. Cryo-EM structures of tau filaments from SH-SY5Y cells seeded with brain extracts from cases of Alzheimer\u2019s disease and corticobasal degeneration. FEBS Open Bio 13, 1394\u20131404 (2023).","journal-title":"FEBS Open Bio"},{"key":"1792_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/alz.094584","volume":"20","author":"A Kasen","year":"2024","unstructured":"Kasen, A. et al. Driving tau pathogenicity seeding\u2014how fibril structure and post-translational modifications alter seeding capacity. Alzheimers Dement. 20, e094584 (2024).","journal-title":"Alzheimers Dement."},{"key":"1792_CR20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/2211-5463.13110","volume":"11","author":"S L\u00f6vestam","year":"2021","unstructured":"L\u00f6vestam, S. et al. Seeded assembly in vitro does not replicate the structures of \u03b1-synuclein filaments from multiple system atrophy. FEBS Open Bio 11, 999\u20131013 (2021).","journal-title":"FEBS Open Bio"},{"key":"1792_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66146-4","volume":"16","author":"F Wang","year":"2025","unstructured":"Wang, F. et al. Seed amplification of MSA alpha-synuclein aggregates preserves the biological and structural properties of brain-derived aggregates. Nat. Commun. 16, 11266 (2025).","journal-title":"Nat. Commun."},{"key":"1792_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46832-5","volume":"15","author":"DD Dhavale","year":"2024","unstructured":"Dhavale, D. D. et al. Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue. Nat. Commun. 15, 2750 (2024).","journal-title":"Nat. Commun."},{"key":"1792_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-05319-3","volume":"610","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Structures of \u03b1-synuclein filaments from human brains with Lewy pathology. Nature 610, 791\u2013795 (2022).","journal-title":"Nature"},{"key":"1792_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41586-025-09698-1","volume":"648","author":"D Burger","year":"2025","unstructured":"Burger, D. et al. Synthetic \u03b1-synuclein fibrils replicate in mice causing MSA-like pathology. Nature 648, 409\u2013417 (2025).","journal-title":"Nature"},{"key":"1792_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.111005","volume":"302","author":"A Raina","year":"2026","unstructured":"Raina, A. et al. Skin-derived \u03b1-synuclein strains from PD, DLB, and MSA induce distinct intracellular pathology and neurodegeneration. J. Biol. Chem. 302, 111005 (2026).","journal-title":"J. Biol. Chem."},{"key":"1792_CR26","doi-asserted-by":"publisher","unstructured":"Sanchez, J. C. et al. Complementary structural and chemical biology methods reveal the basis for selective radioligand binding to \u03b1-synuclein in MSA tissue. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.06.30.662461 (2025).","DOI":"10.1101\/2025.06.30.662461"},{"key":"1792_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1126\/science.abm7285","volume":"375","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Cryo-EM structures of amyloid-\u03b2 42 filaments from human brains. Science 375, 167\u2013172 (2022).","journal-title":"Science"},{"key":"1792_CR28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2218831120","volume":"120","author":"M Lee","year":"2023","unstructured":"Lee, M., Yau, W.-M., Louis, J. M. & Tycko, R. Structures of brain-derived 42-residue amyloid-\u03b2 fibril polymorphs with unusual molecular conformations and intermolecular interactions. Proc. Natl Acad. Sci. USA 120, e2218831120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1792_CR29","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1002\/anie.200906670","volume":"49","author":"SM Butterfield","year":"2010","unstructured":"Butterfield, S. M. & Lashuel, H. A. Amyloidogenic protein\u2013membrane interactions: mechanistic insight from model systems. Angew. Chem. Int. Ed. Engl. 49, 5628\u20135654 (2010).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"1792_CR30","doi-asserted-by":"publisher","first-page":"16357","DOI":"10.1073\/pnas.1906839116","volume":"116","author":"AJ Dregni","year":"2019","unstructured":"Dregni, A. J. et al. In vitro 0N4R tau fibrils contain a monomorphic \u03b2-sheet core enclosed by dynamically heterogeneous fuzzy coat segments. Proc. Natl Acad. Sci. USA 116, 16357\u201316366 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1792_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41582-020-0333-7","volume":"16","author":"C Peng","year":"2020","unstructured":"Peng, C., Trojanowski, J. Q. & Lee, V. M.-Y. Protein transmission in neurodegenerative disease. Nat. Rev. Neurol. 16, 199\u2013212 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"1792_CR32","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41583-022-00603-7","volume":"23","author":"D Li","year":"2022","unstructured":"Li, D. & Liu, C. Conformational strains of pathogenic amyloid proteins in neurodegenerative diseases. Nat. Rev. Neurosci. 23, 523\u2013534 (2022).","journal-title":"Nat. Rev. Neurosci."},{"key":"1792_CR33","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","volume":"21","author":"M Jucker","year":"2018","unstructured":"Jucker, M. & Walker, L. C. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat. Neurosci. 21, 1341\u20131349 (2018).","journal-title":"Nat. Neurosci."},{"key":"1792_CR34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick, A. W. P. et al. Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature 547, 185\u2013190 (2017).","journal-title":"Nature"},{"key":"1792_CR35","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1042\/EBC20210025","volume":"65","author":"M Goedert","year":"2021","unstructured":"Goedert, M. Cryo-EM structures of \u03c4 filaments from human brain. Essays Biochem. 65, 949\u2013959 (2021).","journal-title":"Essays Biochem."},{"key":"1792_CR36","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41586-020-2317-6","volume":"585","author":"M Schweighauser","year":"2020","unstructured":"Schweighauser, M. et al. Structures of \u03b1-synuclein filaments from multiple system atrophy. Nature 585, 464\u2013469 (2020).","journal-title":"Nature"},{"key":"1792_CR37","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.cell.2022.02.026","volume":"185","author":"A Chang","year":"2022","unstructured":"Chang, A. et al. Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. Cell 185, 1346\u20131355 (2022).","journal-title":"Cell"},{"key":"1792_CR38","doi-asserted-by":"publisher","unstructured":"Mahul-Mellier, A.-L. et al. Recapitulating Parkinson\u2019s pathology in human iPSC dopaminergic neurons reveals new mechanistic insights into Lewy body formation and heterogeneity. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.10.26.684610 (2025).","DOI":"10.1101\/2025.10.26.684610"},{"key":"1792_CR39","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1073\/pnas.1913904117","volume":"117","author":"A-L Mahul-Mellier","year":"2020","unstructured":"Mahul-Mellier, A.-L. et al. The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc. Natl Acad. Sci. USA 117, 4971\u20134982 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1792_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq3539","volume":"10","author":"A Sokratian","year":"2024","unstructured":"Sokratian, A. et al. Mouse \u03b1-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases. Sci. Adv. 10, eadq3539 (2024).","journal-title":"Sci. Adv."},{"key":"1792_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.14802\/jmd.23213","volume":"17","author":"A Tarutani","year":"2023","unstructured":"Tarutani, A. & Hasegawa, M. Ultrastructures of \u03b1-synuclein filaments in synucleinopathy brains and experimental models. J. Mov. Disord. 17, 15\u201329 (2023).","journal-title":"J. Mov. Disord."},{"key":"1792_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-01026-0","volume":"8","author":"AJ Schaser","year":"2020","unstructured":"Schaser, A. J. et al. Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy. Acta Neuropathol. Commun. 8, 150 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"1792_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22108-0","volume":"12","author":"VA Trinkaus","year":"2021","unstructured":"Trinkaus, V. A. et al. In situ architecture of neuronal \u03b1-synuclein inclusions. Nat. Commun. 12, 2110 (2021).","journal-title":"Nat. Commun."},{"key":"1792_CR44","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1016\/j.neuron.2024.06.002","volume":"112","author":"I Lam","year":"2024","unstructured":"Lam, I. et al. Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of \u03b1-synuclein inclusions. Neuron 112, 2886\u20132909.e16 (2024).","journal-title":"Neuron"},{"key":"1792_CR45","doi-asserted-by":"publisher","first-page":"9340","DOI":"10.1523\/JNEUROSCI.22-21-09340.2002","volume":"22","author":"B Allen","year":"2002","unstructured":"Allen, B. et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22, 9340\u20139351 (2002).","journal-title":"J. Neurosci."},{"key":"1792_CR46","doi-asserted-by":"publisher","first-page":"40162","DOI":"10.1074\/jbc.M308243200","volume":"278","author":"A Ferrari","year":"2003","unstructured":"Ferrari, A., Hoerndli, F., Baechi, T., Nitsch, R. M. & G\u00f6tz, J. \u03b2-Amyloid induces paired helical filament-like tau filaments in tissue culture. J. Biol. Chem. 278, 40162\u201340168 (2003).","journal-title":"J. Biol. Chem."},{"key":"1792_CR47","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.str.2024.10.013","volume":"32","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Tau seeds catalyze fibril-type structures from GFP tau biosensor cells. Structure 32, 2251\u20132258 (2024).","journal-title":"Structure"},{"key":"1792_CR48","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.neuron.2023.04.020","volume":"111","author":"M Colom-Cadena","year":"2023","unstructured":"Colom-Cadena, M. et al. Synaptic oligomeric tau in Alzheimer\u2019s disease\u2014a potential culprit in the spread of tau pathology through the brain. Neuron 111, 2170\u20132183 (2023).","journal-title":"Neuron"},{"key":"1792_CR49","doi-asserted-by":"publisher","unstructured":"Erwin, A. L. et al. Molecular visualization of neuronal TDP43 pathology in situ. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.08.19.608477 (2025).","DOI":"10.1101\/2024.08.19.608477"},{"key":"1792_CR50","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202153877","volume":"22","author":"P De Rossi","year":"2021","unstructured":"De Rossi, P. et al. FTLD\u2013TDP assemblies seed neoaggregates with subtype-specific features via a prion-like cascade. EMBO Rep. 22, e53877 (2021).","journal-title":"EMBO Rep."},{"key":"1792_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-01084-y","volume":"11","author":"A-L Mahul-Mellier","year":"2025","unstructured":"Mahul-Mellier, A.-L. et al. Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation. NPJ Park. Dis. 11, 261 (2025).","journal-title":"NPJ Park. Dis."},{"key":"1792_CR52","doi-asserted-by":"publisher","first-page":"4988","DOI":"10.1093\/brain\/awad272","volume":"146","author":"A Tarutani","year":"2023","unstructured":"Tarutani, A. et al. Distinct tau folds initiate templated seeding and alter the post-translational modification profile. Brain 146, 4988\u20134999 (2023).","journal-title":"Brain"},{"key":"1792_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.611285","volume":"14","author":"SM Ulamec","year":"2020","unstructured":"Ulamec, S. M., Brockwell, D. J. & Radford, S. E. Looking beyond the core: the role of flanking regions in the aggregation of amyloidogenic peptides and proteins. Front. Neurosci. 14, 611285 (2020).","journal-title":"Front. Neurosci."},{"key":"1792_CR54","doi-asserted-by":"publisher","first-page":"9240","DOI":"10.1038\/s41467-025-64312-2","volume":"16","author":"A Kasen","year":"2025","unstructured":"Kasen, A. et al. Seed structure and phosphorylation in the fuzzy coat impact tau seeding competency. Nat. Commun. 16, 9240 (2025).","journal-title":"Nat. Commun."},{"key":"1792_CR55","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1021\/jacs.5c18540","volume":"148","author":"JY Zhang","year":"2026","unstructured":"Zhang, J. Y., Dregni, A. J. & Hong, M. Heterogeneous dynamics of the fuzzy coat of full-length phospho-mimetic tau fibrils. J. Am. Chem. Soc. 148, 1623\u20131637 (2026).","journal-title":"J. Am. Chem. Soc."},{"key":"1792_CR56","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.neuron.2025.03.019","volume":"113","author":"Y Han","year":"2025","unstructured":"Han, Y. et al. Fibril fuzzy coat is important for \u03b1-synuclein pathological transmission activity. Neuron 113, 1723\u20131740 (2025).","journal-title":"Neuron"},{"key":"1792_CR57","doi-asserted-by":"publisher","first-page":"35770","DOI":"10.1039\/D2RA04358K","volume":"12","author":"M Bopardikar","year":"2022","unstructured":"Bopardikar, M., Ainavarapu, S. R. K. & Hosur, R. V. Pyrogallol, corilagin and chebulagic acid target the \u2018fuzzy coat\u2019 of alpha-synuclein to inhibit the fibrillization of the protein. RSC Adv. 12, 35770\u201335777 (2022).","journal-title":"RSC Adv."},{"key":"1792_CR58","doi-asserted-by":"publisher","first-page":"10723","DOI":"10.1021\/jacs.2c00509","volume":"144","author":"S Nazarov","year":"2022","unstructured":"Nazarov, S., Chiki, A., Boudeffa, D. & Lashuel, H. A. Structural basis of huntingtin fibril polymorphism revealed by cryogenic electron microscopy of exon 1 HTT fibrils. J. Am. Chem. Soc. 144, 10723\u201310735 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"1792_CR59","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41593-023-01341-4","volume":"26","author":"ST Kumar","year":"2023","unstructured":"Kumar, S. T. et al. Seeding the aggregation of TDP-43 requires post-fibrillization proteolytic cleavage. Nat. Neurosci. 26, 983\u2013996 (2023).","journal-title":"Nat. Neurosci."},{"key":"1792_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr7008","volume":"11","author":"M Milanesi","year":"2025","unstructured":"Milanesi, M., Brotzakis, Z. F. & Vendruscolo, M. Transient interactions between the fuzzy coat and the cross-\u03b2 core of brain-derived A\u03b242 filaments. Sci. Adv. 11, eadr7008 (2025).","journal-title":"Sci. Adv."},{"key":"1792_CR61","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.neuron.2025.03.004","volume":"113","author":"J Rummens","year":"2025","unstructured":"Rummens, J. et al. TDP-43 seeding induces cytoplasmic aggregation heterogeneity and nuclear loss of function of TDP-43. Neuron 113, 1597\u20131613 (2025).","journal-title":"Neuron"},{"key":"1792_CR62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41421-023-00637-w","volume":"10","author":"W Zhao","year":"2024","unstructured":"Zhao, W. et al. Cryo-EM structures reveal variant tau amyloid fibrils between the rTg4510 mouse model and sporadic human tauopathies. Cell Discov. 10, 27 (2024).","journal-title":"Cell Discov."},{"key":"1792_CR63","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/s41594-025-01575-9","volume":"32","author":"M Schweighauser","year":"2025","unstructured":"Schweighauser, M. et al. Distinct tau filament folds in human MAPT mutants P301L and P301T. Nat. Struct. Mol. Biol. 32, 1470\u20131478 (2025).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1792_CR64","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cell.2020.01.027","volume":"180","author":"T Arakhamia","year":"2020","unstructured":"Arakhamia, T. et al. Posttranslational modifications mediate the structural diversity of tauopathy strains. Cell 180, 633\u2013644 (2020).","journal-title":"Cell"},{"key":"1792_CR65","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.cell.2020.10.029","volume":"183","author":"H Wesseling","year":"2020","unstructured":"Wesseling, H. et al. Tau PTM profiles identify patient heterogeneity and stages of Alzheimer\u2019s disease. Cell 183, 1699\u20131713 (2020).","journal-title":"Cell"},{"key":"1792_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105536","volume":"161","author":"G Limorenko","year":"2021","unstructured":"Limorenko, G. & Lashuel, H. A. To target tau pathologies, we must embrace and reconstruct their complexities. Neurobiol. Dis. 161, 105536 (2021).","journal-title":"Neurobiol. Dis."},{"key":"1792_CR67","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1021\/acs.jproteome.8b00982","volume":"18","author":"P Bhattacharjee","year":"2019","unstructured":"Bhattacharjee, P. et al. Mass spectrometric analysis of Lewy body-enriched \u03b1-synuclein in Parkinson\u2019s disease. J. Proteome Res. 18, 2109\u20132120 (2019).","journal-title":"J. Proteome Res."},{"key":"1792_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/srep05797","volume":"4","author":"JF Kellie","year":"2014","unstructured":"Kellie, J. F. et al. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson\u2019s disease brain tissue by intact protein mass spectrometry. Sci. Rep. 4, 5797 (2014).","journal-title":"Sci. Rep."},{"key":"1792_CR69","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41593-022-01239-7","volume":"26","author":"S Zhang","year":"2023","unstructured":"Zhang, S. et al. Post-translational modifications of soluble \u03b1-synuclein regulate the amplification of pathological \u03b1-synuclein. Nat. Neurosci. 26, 213\u2013225 (2023).","journal-title":"Nat. Neurosci."},{"key":"1792_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-022-01468-8","volume":"10","author":"MF Altay","year":"2022","unstructured":"Altay, M. F., Liu, A. K. L., Holton, J. L., Parkkinen, L. & Lashuel, H. A. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders. Acta Neuropathol. Commun. 10, 163 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"1792_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74130-z","volume":"14","author":"F Kametani","year":"2024","unstructured":"Kametani, F. et al. Analysis and comparison of post-translational modifications of \u03b1-synuclein filaments in multiple system atrophy and dementia with Lewy bodies. Sci. Rep. 14, 22892 (2024).","journal-title":"Sci. Rep."},{"key":"1792_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00601-y","volume":"18","author":"K Wenger","year":"2023","unstructured":"Wenger, K. et al. Common mouse models of tauopathy reflect early but not late human disease. Mol. Neurodegener. 18, 10 (2023).","journal-title":"Mol. Neurodegener."},{"key":"1792_CR73","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.93562.4","volume":"12","author":"L Frey","year":"2024","unstructured":"Frey, L. et al. On the pH-dependence of \u03b1-synuclein amyloid polymorphism and the role of secondary nucleation in seed-based amyloid propagation. eLife 12, RP93562 (2024).","journal-title":"eLife"},{"key":"1792_CR74","doi-asserted-by":"publisher","unstructured":"Sadek, A., Correia, B. E. & Lashuel, H. A. Mapping the structural landscape of amyloid fibrils to guide polymorph-specific therapeutics. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.05.08.652887 (2025).","DOI":"10.1101\/2025.05.08.652887"},{"key":"1792_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104582","volume":"132","author":"DJ Schofield","year":"2019","unstructured":"Schofield, D. J. et al. Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo. Neurobiol. Dis. 132, 104582 (2019).","journal-title":"Neurobiol. Dis."},{"key":"1792_CR76","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12770-x","volume":"272","author":"M Alfaidi","year":"2024","unstructured":"Alfaidi, M., Barker, R. A. & Kuan, W.-L. An update on immune-based alpha-synuclein trials in Parkinson\u2019s disease. J. Neurol. 272, 21 (2024).","journal-title":"J. Neurol."},{"key":"1792_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-01117-6","volume":"11","author":"S An","year":"2025","unstructured":"An, S. et al. A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies. NPJ Park. Dis. 11, 254 (2025).","journal-title":"NPJ Park. Dis."},{"key":"1792_CR78","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/35081095","volume":"411","author":"GP Saborio","year":"2001","unstructured":"Saborio, G. P., Permanne, B. & Soto, C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411, 810\u2013813 (2001).","journal-title":"Nature"},{"key":"1792_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001217","volume":"6","author":"JM Wilham","year":"2010","unstructured":"Wilham, J. M. et al. Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog. 6, e1001217 (2010).","journal-title":"PLoS Pathog."},{"key":"1792_CR80","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm.2294","volume":"17","author":"R Atarashi","year":"2011","unstructured":"Atarashi, R. et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat. Med. 17, 175\u2013178 (2011).","journal-title":"Nat. Med."},{"key":"1792_CR81","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson\u2019s progression markers initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407\u2013417 (2023).","journal-title":"Lancet Neurol."},{"key":"1792_CR82","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cbpa.2021.05.007","volume":"64","author":"SP Moon","year":"2021","unstructured":"Moon, S. P., Balana, A. T. & Pratt, M. R. Consequences of post-translational modifications on amyloid proteins as revealed by protein semisynthesis. Curr. Opin. Chem. Biol. 64, 76\u201389 (2021).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"1792_CR83","doi-asserted-by":"publisher","first-page":"6611","DOI":"10.1021\/jacs.8b02668","volume":"140","author":"M Haj-Yahya","year":"2018","unstructured":"Haj-Yahya, M. & Lashuel, H. A. Protein semisynthesis provides access to tau disease-associated post-translational modifications (PTMs) and paves the way to deciphering the tau PTM code in health and diseased states. J. Am. Chem. Soc. 140, 6611\u20136621 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"1792_CR84","doi-asserted-by":"publisher","first-page":"9254","DOI":"10.1039\/c3cc45353g","volume":"49","author":"B Fauvet","year":"2013","unstructured":"Fauvet, B., Butterfield, S. M., Fuks, J., Brik, A. & Lashuel, H. A. One-pot total chemical synthesis of human \u03b1-synuclein. Chem. Commun. 49, 9254\u20139256 (2013).","journal-title":"Chem. Commun."},{"key":"1792_CR85","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s40478-021-01288-2","volume":"9","author":"NP Marotta","year":"2021","unstructured":"Marotta, N. P. et al. Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro. Acta Neuropathol. Commun. 9, 188 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"1792_CR86","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.1038\/s41467-023-42705-5","volume":"14","author":"N Uemura","year":"2023","unstructured":"Uemura, N. et al. \u03b1-Synuclein aggregates amplified from patient-derived Lewy bodies recapitulateLewy body diseases in mice. Nat. Commun. 14, 6892 (2023).","journal-title":"Nat. Commun."},{"key":"1792_CR87","doi-asserted-by":"publisher","unstructured":"Joly, J. et al. Development of a method for large-scale single-molecule analysis of tau proteoforms. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.06.26.660445 (2025).","DOI":"10.1101\/2025.06.26.660445"},{"key":"1792_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/smsc.202500351","volume":"5","author":"C Marcuello","year":"2025","unstructured":"Marcuello, C. et al. Nanoscale analysis beyond imaging by atomic force microscopy: molecular perspectives on oncology and neurodegeneration. Small Sci. 5, 2500351 (2025).","journal-title":"Small Sci."},{"key":"1792_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/srep31155","volume":"6","author":"FS Ruggeri","year":"2016","unstructured":"Ruggeri, F. S. et al. Nanoscale studies link amyloid maturity with polyglutamine diseases onset. Sci. Rep. 6, 31155 (2016).","journal-title":"Sci. Rep."},{"key":"1792_CR90","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1039\/D1CS00127B","volume":"51","author":"G Limorenko","year":"2022","unstructured":"Limorenko, G. & Lashuel, H. A. Revisiting the grammar of tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies. Chem. Soc. Rev. 51, 513\u2013565 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"1792_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116564","volume":"44","author":"T Cao","year":"2025","unstructured":"Cao, T. et al. In situ amplification of \u03b1-synuclein amyloid fibril reveals a distinct polymorph related to Parkinson\u2019s disease and dementia with Lewy body. Cell Rep. 44, 116564 (2025).","journal-title":"Cell Rep."},{"key":"1792_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/cells14181418","volume":"14","author":"M Higuchi","year":"2025","unstructured":"Higuchi, M. Imaging of proteinopathies in the brains of Parkinsonian disorders. Cells 14, 1418 (2025).","journal-title":"Cells"},{"key":"1792_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67457-2","volume":"17","author":"J Yu","year":"2026","unstructured":"Yu, J. et al. Structure of ATTRv-F64S fibrils isolated from skin tissue of a living patient. Nat. Commun. 17, 781 (2026).","journal-title":"Nat. Commun."}],"container-title":["Nature Structural & Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41594-026-01792-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41594-026-01792-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41594-026-01792-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:06:34Z","timestamp":1776701194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41594-026-01792-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1792"],"URL":"https:\/\/doi.org\/10.1038\/s41594-026-01792-w","relation":{},"ISSN":["1545-9993","1545-9985"],"issn-type":[{"value":"1545-9993","type":"print"},{"value":"1545-9985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.A.L. is a cofounder and chief scientific officer of ND BioSciences, a company focusing on developing novel therapies and diagnostics for NDDs. He has received funding from the Michael J. Fox Foundation AC Immune, UCB, Idorsia and AbbVie for projects on the role of protein aggregation in neurodegenerative diseases. These funders had no bearing on the preparation of this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}